KLRK1 and cancer: Li et al. [83] generated a novel iPSC-derived CAR-NK cell product targeting mesothelin containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain to potentiate cancer cell killing.